Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HSV-2 transmission.

S L Sacks1, P D Griffiths, L Corey

  • 1Viridae, Vancouver, Canada.

Antiviral Research
|September 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation of Positive Advanced Recovery Connections in Primary and Secondary Mental Health Care-A Registered Advanced Nurse Practitioner-Led Initiative.

Journal of advanced nursing·2024
Same author

Gut microbiota analysis and faecal transplantation to improve surgical outcomes.

The British journal of surgery·2023
Same author

Chemical characterisation of the vapour emitted by an e-cigarette using a ceramic wick-based technology.

Scientific reports·2022
Same author

Conservation in a Region of Political Instability: Bwindi Impenetrable Forest, Uganda.

Conservation biology : the journal of the Society for Conservation Biology·2022
Same author

Quality of internet information to aid patient decision making in locally advanced and recurrent rectal cancer.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2022
Same author

The Chemical Complexity of e-Cigarette Aerosols Compared With the Smoke From a Tobacco Burning Cigarette.

Frontiers in chemistry·2021
Same journal

Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention.

Antiviral research·2026
Same journal

The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.

Antiviral research·2026
Same journal

Ginsenoside Rb2-based inactivation enables a Zika vaccine that maintains pregnancy and protects offspring against virus.

Antiviral research·2026
Same journal

ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.

Antiviral research·2026
Same journal

Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].

Antiviral research·2026
Same journal

Effects of RNA polymerase inhibitors on nucleotidylylation of human norovirus VPg.

Antiviral research·2026
See all related articles

Valaciclovir can prevent the sexual transmission of herpes simplex virus type 2 (HSV-2) between partners. This antiviral agent offers a new strategy for controlling this common sexually transmitted infection (STI).

Area of Science:

  • Virology
  • Epidemiology
  • Public Health

Background:

  • Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted infection (STI) with established risk factors including gender, ethnicity, HIV status, age, and number of sexual partners.
  • Transmission is influenced by sexual behavior, condom use, relationship duration, and awareness of a partner's infection status.
  • Vertical transmission from mother to neonate poses life-threatening risks, leading to significant morbidity and mortality.

Purpose of the Study:

  • To review factors influencing HSV-2 transmission.
  • To explore the role of antiviral agents in preventing HSV-2 transmission.
  • To make recommendations for prophylactic antiviral use in at-risk populations.

Main Methods:

  • Review of existing literature on HSV-2 transmission and risk factors.

Related Experiment Videos

  • Analysis of data from the valaciclovir transmission study.
  • Exploration of biological and behavioral cofactors affecting transmission.

    • Main Results:

    • The valaciclovir transmission study demonstrated that antiviral therapy can interrupt HSV-2 transmission between serologically discordant partners.
    • Identified key risk factors and cofactors influencing HSV-2 acquisition and transmission.

    Conclusions:

    • Antiviral agents, such as valaciclovir, show promise in preventing the sexual transmission of HSV-2.
    • Prophylactic use of antivirals warrants consideration for specific patient populations to reduce HSV-2 transmission and its associated risks.